Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial

BACKGROUND: Dipeptidyl peptidase 4 (DPP4) inhibitors improve glycemic control by promoting GLP1-mediated glucose-dependent insulin secretion and suppression of glucagon. Sitagliptin and vildagliptin have been shown to improve insulin sensitivity in patients with type 2 diabetes mellitus (T2DM). Howe...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Pharmacol Toxicol
Autori principali: Parthan, Girish, Bhansali, Shobhit, Kurpad, Anura V., Walia, Rama, Bhat, Kishor, Bhansali, Anil
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2018
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6030784/
https://ncbi.nlm.nih.gov/pubmed/29970184
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40360-018-0228-z
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi